Beaufort Securities reissued their speculative buy rating on shares of Tiziana Life Sciences (LON:TILS) in a research report released on Tuesday. The firm currently has a GBX 400 ($5.38) price objective on the biotechnology company’s stock.
Tiziana Life Sciences (LON TILS) opened at GBX 148.55 ($2.00) on Tuesday. Tiziana Life Sciences has a twelve month low of GBX 102.06 ($1.37) and a twelve month high of GBX 240 ($3.23).
Tiziana Life Sciences (LON:TILS) last issued its earnings results on Friday, September 29th. The biotechnology company reported GBX (4.10) (($0.06)) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of GBX (2) (($0.03)) by GBX (2.10) (($0.03)).
TRADEMARK VIOLATION WARNING: “Tiziana Life Sciences’ (TILS) “Speculative Buy” Rating Reaffirmed at Beaufort Securities” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://sportsperspectives.com/2017/12/20/tiziana-life-sciences-tils-speculative-buy-rating-reaffirmed-at-beaufort-securities.html.
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.